Anticoagulation in Cirrhosis

Introduction to Anticoagulation

Anticoagulation is a key component of treatment for patients with cirrhosis, particularly those with portal vein thrombosis (PVT), as recommended by the American Gastroenterological Association and the American College of Gastroenterology 1, 2

For patients with Child-Pugh A or B cirrhosis, the American Society of Hematology recommends either Direct Oral Anticoagulants (DOACs) or Low Molecular Weight Heparin (LMWH) with/without Vitamin K Antagonists (VKAs) based on patient preference 2
For patients with Child-Pugh C cirrhosis, Low Molecular Weight Heparin (LMWH) alone is recommended, or as a bridge to Vitamin K Antagonists (VKAs) in patients with normal baseline International Normalized Ratio (INR) 2
Anticoagulation options include:
- Low molecular weight heparin (LMWH), with monitoring of anti-Xa activity (target 0.5-0.8 IU/ml) in overweight patients, pregnancy, or poor kidney function 2, 3, 1
- Vitamin K antagonists (VKAs) with target INR 2-3 2, 1
- Direct oral anticoagulants (DOACs) for patients with compensated Child-Turcotte-Pugh class A and B cirrhosis 2, 1

The following diagnostic modalities can be used for PVT:

Diagnostic Modality	Description
Doppler Ultrasound	First-line investigation for PVT
Contrast-Enhanced CT Scan	Diagnostic modality of choice, showing filling defects, mesenteric venous engorgement, fat-stranding, and edema

Doppler ultrasound serves as the first-line investigation for PVT, with confirmation by contrast-enhanced CT scan during the portal phase showing filling defects, mesenteric venous engorgement, fat-stranding, and edema 3, 4, 5

Anticoagulation should not be withheld in patients with moderate thrombocytopenia secondary to advanced liver disease, and decisions should be made on a case-by-case basis when platelet count is <50 × 10^9/L, considering site and extent of thrombosis, risk of thrombus extension, patient preference, and presence of active bleeding or additional bleeding risk factors 2
High bleeding risk, especially with esophageal varices and portal hypertension, is a contraindication for anticoagulation 1
Severe thrombocytopenia and fall risk with frailty are also contraindications for anticoagulation 1

Anticoagulation should be initiated immediately in patients with recent (<6 months) PVT that is >50% occlusive or involves the main portal vein or mesenteric vessels, while observation with serial imaging is appropriate for patients with <50% occlusion or intrahepatic branch involvement, as recommended by the American Gastroenterological Association 1
Immediate anticoagulation is indicated, with higher benefit in transplant candidates, multiple vascular bed involvement, thrombus progression, and inherited thrombophilia, according to the American Gastroenterological Association 1
The American Gastroenterological Association recommends a minimum of 6 months of anticoagulation, with continuation until complete clot resolution in non-transplant candidates, until transplantation in transplant candidates, or lifelong in permanent hypercoagulable states 1
Cross-sectional imaging every 3 months is recommended to assess response to anticoagulation, as suggested by the American Gastroenterological Association 1
Expected recanalization rates with anticoagulation: 38-39% for portal vein, 54-80% for splenic vein, and 61-73% for superior mesenteric vein 3, 6, 1

Early initiation of anticoagulation (within 2 weeks) improves recanalization rates, according to the American Gastroenterological Association 1
Anticoagulation improves survival (HR: 0.59; 95% CI: 0.49-0.70) and does not increase portal hypertensive bleeding risk 2, 3, 1
Do not delay anticoagulation for variceal screening, as this decreases recanalization rates, as recommended by the American Gastroenterological Association 1
Transjugular intrahepatic portosystemic shunting (TIPS) may be considered for patients with additional indications (refractory ascites, variceal bleeding) or transplant candidates to facilitate technical feasibility, according to the American Gastroenterological Association 1
Intestinal ischemia due to PVT is a medical emergency requiring immediate inpatient care, urgent anticoagulation, and multidisciplinary management 1
Consider interventional approaches, such as thrombectomy or thrombolysis, if no clinical improvement with anticoagulation 1

A multidisciplinary approach involving gastroenterology, interventional radiology, surgery, and hematology is recommended for managing PVT 1
Transfer to a specialized center is recommended if multidisciplinary services are unavailable 1